MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

Pliant Therapeutics Inc

Cerrado

1.47 1.38

Resumen

Variación precio

24h

Actual

Mínimo

1.41

Máximo

1.47

Métricas clave

By Trading Economics

Ingresos

8M

-50M

BPA

-0.82

Empleados

171

EBITDA

7.9M

-48M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+259.59% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

6.7M

91M

Apertura anterior

0.09

Cierre anterior

1.47

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Pliant Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2025, 23:27 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 abr 2025, 23:07 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 abr 2025, 23:03 UTC

Ganancias

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 abr 2025, 23:47 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 abr 2025, 22:57 UTC

Principales Noticias

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 abr 2025, 22:46 UTC

Ganancias

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

259.59% repunte

Estimación a 12 meses

Media 5.25 USD  259.59%

Máximo 17 USD

Mínimo 1.5 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

13 ratings

2

Comprar

11

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.41 / 1.46Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.